NKY(SZ:300109) Xin Lang Cai Jing·2025-10-24 01:45Group 1 - On October 23, Xin Kai Yuan's stock decreased by 0.73%, with a trading volume of 82.59 million yuan [1] - The financing data shows that on the same day, Xin Kai Yuan had a financing buy-in amount of 11.58 million yuan and a financing repayment of 20.01 million yuan, resulting in a net financing outflow of 8.43 million yuan [1] - As of October 23, the total balance of margin trading for Xin Kai Yuan was 819 million yuan, with the financing balance accounting for 10.30% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Xin Kai Yuan Medical Technology Group Co., Ltd. was established on March 13, 2003, and listed on August 25, 2010, with its main business involving the research, production, and sales of PVP series products and other high-value-added pharmaceutical excipients [2] - The revenue composition of Xin Kai Yuan includes: PVP Others 39.57%, PVPK30 Powder 28.35%, Oruisi Series 14.80%, PVP-I 6.85%, Precision Medical Services 3.45%, Early Cancer Diagnosis 3.08%, Genetic Testing Technology 3.04%, and Molecular Diagnostic Services 0.87% [2] - For the first half of 2025, Xin Kai Yuan reported an operating income of 644 million yuan, a year-on-year decrease of 12.36%, and a net profit attributable to the parent company of 139 million yuan, down 34.74% year-on-year [2] Group 3 - Since its A-share listing, Xin Kai Yuan has distributed a total of 900 million yuan in dividends, with 607 million yuan distributed over the past three years [3]